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Sonic Hedgehog-Patched-1 signaling in craniofa-
cial anomalies and cancers
 Sonic hedgehog (SHH) is a mammalian homolog of 
Drosophila hedgehog (hh), which leads to the activation 
and repression of target genes, and sets off a chain of 
events in target cells1.  SHH has a role in establishing 
left-right body determination, central nervous system 
development, somite patterning, eye development and 
limb patterning.  The receptor for SHH, Patched-1 
(PTCH1), is a human homolog of patched Drosophila 
segment polarity gene2,3, and it appears to have a tumor 
suppressor role, at least in some malignancies for which 
the syndrome predisposes, as has been most convincing-
ly demonstrated for basocellular carcinomas.  Its pro-
tein product, located in the plasma membrane, is an ele-
ment of the Shh-PTCH1 signaling pathway.  PTCH1 
inhibits the seven-transmembrane signaling protein 
smoothened (SMO).  Upon binding of SHH ligand to 
PTCH1, the PTCH1 inhibition of SMO is relieved, and 
the transcription factor Gli1 activates target genes, in-
cluding WNT, BMP, GLI1, Patched2, HIP and Patched-1 
itself, resulting in a negative feedback loop4.  Dysregu-
lation of the SHH-PTCH1 pathway leads to several hu-
man diseases, including birth defects and cancers.  Loss 
of SHH signaling in the chick embryonic face causes de-
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fects similar to the cleft lip/palate and hypotelorism in 
humans5, and PTCH1 mutation has been reported to be 
responsible for nevoid basal cell carcinoma syndrome 
(NBCCS)/Gorlin syndrome3.  NBCCS is an autosomal 
dominant disorder, which is characterized by predispo-
sition to basal cell carcinomas and several other tumors, 
including ovarian ﬁ broma and medulloblastoma.  Devel-
opmental defects are another prominent feature of the 
syndrome, including pits of the palms and soles, jaw 
keratocysts and other dental malformations, midline 
brain malformations, strabismus, spine and rib abnor-
malities, ectopic calciﬁ cations, and macrocephaly with a 
characteristic coarse face and generalized over-growth6. 
However, the syndrome is particularly noted for its ex-
tensive interfamilial as well as intrafamilial variability 
with respect to the manifestation and severity of the 
phenotype.  The criteria for the diagnosis of NBCCS in-
clude presence of at least two major features of the syn-
drome.  Many PTCH1 mutations in Caucasian and Afri-
can-American NBCCS patients have been reported, 
however, among the Japanese population, there have 
been few reports.
 Here we describe a novel SHH missense mutation in 
a 4-month-old baby with median cleft lip/mandible, and 
PTCH1 mutations in Japanese NBCCS.
1. SHH mutation in oral clefts
 The boy was born at 40-weeks gestation to healthy 
non-consanguineous parents.  There was no family his-
tory of dental or craniofacial anomalies.  At birth, agen-
esis in the mandibular inferior border was recognized 
(Fig. 1A).  The cleft existed in the center of the lower 
lip, and continued to the gum.  The mandibular alveolus 
part was missing, and the splinter of bone on either side 
was movable.  X-Ray and CT view showed that the 
mandibular defect was in the central part.  Moreover, 
the boy suffered from congestive heart failure, tetralogy 
of Fallot (TOF), hepatomegalia, pulmonary hyperten-
sion, and valvular disease of the heart.
 Genomic DNA was prepared from peripheral blood 
leukocytes.  Each of the 3 exons comprising the SHH 
gene was separately ampliﬁ ed.  PCR products were ana-
lyzed by using PCR-SSCP and direct sequence analysis. 
PCR-SSCP of exon 1 showed a band shift in patient 
sample (Fig. 1B).  Sequencing analysis revealed that 
the patient has a 279 C > T mutation in the human 
SHH coding region resulting in a Val for Ala substitu-
tion (A43V).
 Multiple examples of cosegregation with heterozygous 
SHH gene deletions or truncations have demonstrated 
haploinsufﬁ ciency of SHH gene function in holoprosen-
cephary (HPE).  HPE is a complex developmental ﬁ eld 
defect of the forebrain in which the cerebral hemi-
spheres fail to split into distinct halves.  Associated cra-
niofacial anomalies can vary widely, including midline 
cleft palate, cyclopia, proboscis-like nasal structure and 
premaxillary agenesis7–9.  Cleft lip/palate is a typical 
malformation in the craniofacial region.  The frequency 
of cleft lip with or without cleft palate in Japan is 1 per 
500 births.  The factors underlying cleft lip/palate are 
considered to be mutant genes, chromosomal aberra-
tions, environmental teratogens and multifactorial in-
heritance10.  It has been reported that over 50 syn-
dromes include cleft lip/palate as one manifestation, 
and gene mutations were identiﬁ ed in 60% of them.  Is 
SHH a candidate gene for oral clefts?  This is a question 
at issue.  Muenke et al. and Odent et al. published that 
16% of oral clefts without HPE had SHH mutations11. 
Fig. 1　Craniofacial phenotype of a median cleft lip/mandibular patient and PCR-SSCP 
of sonic hedgehog gene.
 (A) : Craniofacial phenotype of the patient. (B) : The patient was heterozygous for 
a PCR-SSCP variant in exon 1 that was not present in the normal control.
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Ieda et al. analyzed 220 South American newborns with 
nonsyndromic cleft lip/palate for SHH mutation, howev-
er, they concluded that mutations in the coding region 
and in the exon-intron boundaries of SHH are not com-
mon in patients with oral cleft12.  Among oral clefts, me-
dian clefts are 0.43–0.73%10, and median cleft mandible 
is rather rare : there are less than 10 cases in Japan. 
The case we experienced is very rare ; the patient not 
only has oral clefts but also suffers from circulatory and 
digestive systemic diseases, such as congestive heart 
failure, tetralogy of Fallot (TOF), hepatomegalia and 
pulmonary hypertension.  We wonder whether this is a 
rare syndrome which has not been identiﬁ ed yet.  Gara-
velli's research group reported a patient with solitary 
median maxillary central incisor syndrome (SMMCI), 
who has V332A substitution in SHH13.  SMMCI is a 
rare dental anomaly which has been reported in cases of 
HPE with autosomal dominant inheritance and SMMCI 
syndrome.  Interestingly, the SHH mutation in our case 
is A43V, and further studies will be required to deter-
mine the role of Ala↔ Val substitution in causing oral 
clefts.  In spite of a large amount of literature on the 
etiology of cleft lip/palate, knowledge of the subject is 
still insufﬁ cient and confused.  To date, no report about 
SHH mutation in cleft mandible has been published, 
and our result indicates that SHH might a candidate 
gene for oral clefts.
2. Patched-1 (PTCH1) mutations in nevoid basal 
cell carcinoma (NBCCS)/Gorlin syndrome
 We examined a Japanese NBCCS family (ﬁ ve NBCCS 
patients and three healthy family members) (Fig. 2) and 
ﬁ ve NBCCS individuals.  Clinical features of familial 
NBCCS patients are summarized in Table 1.
 We screened mutations in all PTCH1 exons (except 
exon 1) and introns.  PTCH1 mutations were identiﬁ ed 
in 7 out of 10 Japanese NBCCS patients and one nor-
mal family member examined in this study.  In the 
NBCCS family, three novel PTCH1 mutations were de-
tected, including 3487insAA in exon 19, Gln 853 Lys in 
exon 15, and 3075＋ 21 G→ A in intron 17.  3487insAA 
was detected in all patients (No. 1, 2, 4, 5, 7) in the fam-
ily.  On the other hand, Gln 853 Lys and 3075＋ 21 G→
A were found in a normal family member (No. 8, Table 
1).  Immunohistochemical study revealed that epithelial 
cells in NBCCS jaw cysts showed high proliferation ac-
tivity indicating high risk of recurrence.  In fact, all fa-
miliar patients suffered local recurrence several times 
(data not shown).
 In addition, one patient showed 2922insTG in exon 17 
and a 1875C > T in exon 12 (silent mutation), and an-
other one showed 1892delC in exon 12.  These two dele-
tion/insertion mutations result in a frame shift and in-
troduction of a premature termination codon.
 Patched-1 is predicted to contain 12 transmembrane 
domains, sterol sensing domain (SSD) ranging from the 
second to the sixth transmembrane domain, and two 
large extracellular loops.  SSD is a very important re-
gion in patched-1, since (a) SSD has a role in vesicular 
trafﬁ cking of cholesterol and other lipids14.   (b) The 
C-terminal region is in close proximity to SSD and to-
gether with N-terminus forms a domain involved in 
SMO inhibition.  Extracellular loops of patched-1 are 
conﬁ rmed to be SHH binding sites15, so mutations in the 
loops might result in ligand-independent constitutive 
activation.  By reviewing the previously reported 
PTCH1 mutations in Japanese NBCCS patients, we 
found that the mutations were mainly concentrated in 
SSD and the predicted two large extracellular loops, es-
pecially the second loop.  The two novel PTCH1 muta-
tions we found, Glu853Lys and 2922insTG, were located 
in the second extracellular loop, 1875C > T in SSD, and 
3487insAA in C-terminus (Fig. 3).  Our ﬁ ndings suggest 
that different domains in patched-1 protein are of spe-
cial importance for NBCCS development, and PTCH1 
mutations in different sites might be correlated with 
phenotypic variability in NBCCS.
Fig. 2　Pedigree of a NBCCS family.
Number 1, 2, 4, 5, 7 were diagnosed as Gorlin syndrome. 
Affected members are shown by closed symbols, the nonaf-
fected by open symbols, presumably affected by shadow 
symbols, and members not examined by NE.
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Mutations in Receptor Tyrosine Kinases
 Receptor tyrosine kinases (RTKs) play pivotal roles in 
regulating and coordinating aspects of cell growth, differ-
entiation and apoptosis.  Ligand binding to the extracel-
lular domain of RTKs results in receptor dimerization 
and transphosphorylation of tyrosine residues in the in-
tracellular domain.  Tie2 and ﬁ broblast growth factor 
receptor (FGFR) are typical RTKs.  Tie2 is an endotheli-
um-speciﬁ c receptor tyrosine kinase, which collaborates 
with vascular endothelial growth factor (VEGF) in regu-
lating angiogenesis and vascular maturation16,17.  Tie2 
activity is normally regulated by the opposing actions of 
agonistic and antagonistic ligands.  Angiopoietin-1 
(Ang1) induces phosphorylation of Tie2 in cultured en-
dothelial cells (ECs), whereas angiopoietin-2 (Ang2) 
competitively inhibits activation of Tie2 by preventing 
Ang1 stimulation18–20.  Mutational analysis of the Tie2 
locus by gene targeting has demonstrated that stringent 
regulation of Tie2 phosphorylation is crucial to correct 
vascular assembly and recruitment of pericytes.  Pa-
tients with inherited venous malformation have been 
found to have an activating mutation, R849W or Y897S, 
in the tyrosine kinase domain of the Tie2 gene21,22). 
These malformed vessels are characterized by a dispro-
portionately large number of ECs versus smooth muscle 
cells, suggesting that Tie2 plays a critical role in EC-
pericytes communication during vascular morphogene-
sis.
 The FGFR family, represented by four major trans-
membrane receptors, plays an important role in normal 
angiogenesis and embryonic development.  Mutations in 
FGFRs could produce an altered balance of splice forms, 
change the balance of homo/hetero-dimers, reducing sig-
naling by dominant negative effect or produce constitu-
tive active dimers.  Mutations in FGFR2 on 10q26 are 
found in Crouzon, Jackson-Weiss, Pfeiffer and Apert 
syndromes, while mutations in FGFR3 at 4q16 produce 
achondroplasia, thanatophoric dysplasia hypochondro-
plasia, Crouzon syndrome with acanthosis nigricans 
and Muencke's coronal craniosynostosis23.  Most normal 
tissues and tumors express multiple FGFRs, including 
splice variants of each.  We have previously reported 
that all four FGFRs, including FGFR1c, FGFR2b, 
FGFR3b and FGFR4 were exclusively expressed in cells 
derived from normal oral epithelia and oral squamous 
cell carcinomas (OSCC)24.  The growth of normal epithe-
lial cells was stimulated by FGFs while OSCC cell pro-
liferation was not25.  Mutations in FGFR genes have 
been reported in human bladder, cervical, gastric and 
colorectal carcinomas26,27, however no such mutations 
have been reported in OSCC.
 Here we describe Tie2 mutations in intramuscular 
haemangiomas (IMHs) and FGFR3b mutation in a se-
ries of human OSCC.
1. Tie2 signaling in intramuscular haemangiomas 
(IMHs)
 Intramuscular haemangiomas (IMHs) are benign vas-
cular tumors characterized by inﬁ ltrating growth in 
skeletal muscle.  IMHs are divided into capillary, cav-
Table 1　 Summary of the clinical phenotype and PTCH1 mutations in familial NBCCS. The nucleotide and amino acid num-
bering is based on GenBank entry NM_000264.2, where the A of ATG initiation codon represents nucleotide ＋1.
Patient Phenotype Mutations
JC P HS BS CFC AK 3487insAA Gln 853 Lys 3075＋21 G→A
No. 1 ＋ ＋ ＋ ＋ ＋
No. 2 ＋ ＋ ＋ ＋ ＋
No. 3
No. 4 ＋ ＋ ＋ ＋ ＋ ＋ ＋ ＋ ＋
No. 5 ＋ ＋ ＋
No. 6 ＋
No. 7 ＋ ＋ ＋ ＋ ＋ ＋ ＋
No. 8 ＋ ＋
JC = Jaw Cysts ; P = Pits ; HS = Hyposcoliosis ; BS = Bridging of Sella ; CFC = Calciﬁ cation of Falx Cerebri ; AK = Abnormal 
Karyotype ; ins = Insertion ; Gln = Glutamine ; Lys = Lysine
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ernous, or mixed type depending on their gross and mi-
croscopic appearances.  The capillary type is composed 
of a disordered proliferation of small vessels, whereas 
the cavernous type is composed of large, thin-walled, di-
lated vessels by ﬂ attened endothelial cells.  More than 
18% of patients suffered local recurrence after surgical 
ablation, but the precise pathogenic mechanisms of 
IMHs are unclear.
 We identiﬁ ed two point mutations in the Tie2 kinase 
domain from 37 haemangioma parafﬁ n-embedded sec-
tions : a G2646A change resulting in a glycine to aspar-
tic acid substitution at residue 833 (G833D) in eight un-
related patients and another A2659T change resulting 
in a glutamine to histidine substitution at residue 837 
(Q837H) in one patient.  A relative of these patients did 
not have a history of IMH.  All of the patients with the 
G833D mutation had a large disﬁ guring lesion affecting 
one side of the face, and associated early post-operative 
recurrence (Fig. 4A), whereas the patient with the 
Q837H mutation had no recurrence during postopera-
tive follow-up after ﬁ ve years (Fig. 4B).  Immunohisto-
chemical analysis of G833D IMHs indicated that the ex-
pression of VEGF protein was up-regulated when 
compared to human normal muscular tissue.  However, 
the expression of VEGF was unable to be detected in 
the ECs of Q837H tumor.  Pathological evaluation re-
vealed that the G833D IMHs were capillary type, 
Fig. 3　Distribution of germline mutations in Japanese NBCCS patients.
The closed triangle denotes de novo missense mutation, the shadow square de-
notes a deletion/insertion mutation, the circle denotes a silent mutation, and the 
star denotes a novel mutation we found. The thick dotted line denotes the SSD.
Fig. 4　Tie2 mutations in human intramuscular 
haemangiomas.
 (A) : The patients with the G833D 
(G2646A) mutation had a large disﬁ gur-
ing lesion affecting one side of the face, 
and associated early post-operative recur-
rence. (B) : The patient with the Q837H 
(A2659T) mutation had no recurrence 
during postoperative follow-up after ﬁ ve 
years.
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whereas the Q837H lesion was an IMH of the cavernous 
type28.
 Murine ECs overexpressing G833DTie2 exhibited an in-
crease in cell proliferation at low serum concentrations, 
high level of VEGF expression and developed angiosar-
comas in nude mice, whereas cells overexpressing either 
wild-typeTie2 or Q837HTie2 failed to elicit these responses. 
Furthermore, G833DTie2 showed a 2.9-fold increase in li-
gand-independent tyrosine autophosphorylation relative 
to wild-type Tie2, whereas Q837HTie2 showed a 20-fold in-
crease relative to wild-type Tie2.  Consistent with their 
ligand-independent phosphorylation, G833DTie2 and 
Q837HTie2 stimulated activation of STAT3, however, wild-
type Tie2 did not exhibit phosphorylation of STAT3 
without ligand stimulation (data not shown)28.
2. FGFR3b mutation in oral squamous cell carci-
nomas (OSCC)
 A G to T mutation at nucleotide position 2128 in the 
human FGFR3b coding region resulting in a Cys for Gly 
substitution (G697C) in the tyrosine kinase domain was 
observed in 62% (44/71) of OSCC parafﬁ n-embedded 
sections.  Immunostained FGFR3b was found in the cy-
toplasm of prickle cells in normal epithelia, and 
FGFR3b was localized in the cytoplasm and nucleus in 
non-FGFR3b mutant OSCC.  Overexpressed FGFR3b 
protein on plasma membranes was noted in OSCC bear-
ing the FGFR3b mutation.  The G697C amino acid sub-
stitution in the kinase domain of FGFR3 resulted in 
23-fold increase in tyrosine kinase activity in compari-
son with the wild-type (data not shown)29.
 We found three common features between Tie2 muta-
tions and FGFR3 mutation.  In the ﬁ rst one, the muta-
tions are located in the second half of tyrosine kinase ; 
in the second one, mutant residues are very important 
for the molecular structure and function.  The G833D 
mutation in Tie2 occurs at the second glycine residue of 
the GXGXXG motif (residues 832–835) within the nu-
cleotide-binding loop in the second half of tyrosine ki-
nase, whereas Q837H affects the glutamine adjacent to 
the third glycine.  Structural analysis suggests that 
these residues around G833, such as E832, N834, and 
F835, form a self-inhibitory conformation with the 
neighboring molecule as a safeguard against abnormal 
ATP binding30.  Incorporation of the much larger aspar-
tic acid at residue 833 may destabilize the self-inhibito-
ry conformation, thus locking it in the ATP-binding 
state38.  In the case of G697CFGFR3b in OSCC, glycine is 
substituted by cysteine.  Because it lacks side chain, 
glycine is able to participate in extremes of bending and 
folding of the polypeptide backbone and it is the stron-
gest breaker of α-helices.  Glycine provides the ﬂ exibili-
ty necessary for anchoring the triphosphate moiety of 
ATP in the correct position for catalysis31.  Therefore, 
mutations at these glycines may directly affect the ATP 
or ADP binding and the hydrolysis of ATP.  Cysteine is 
an important amino acid for maintaining biological ac-
tivity of proteins since it affects protein conformation 
through the formation of intra- and inter-molecular di-
sulﬁ de bonds32.
 The third common feature is that the mutations re-
sult in constitutive activation in tyrosine kinase.  Our 
results showed that G833D and Q837H mutations in 
Tie2 result in ligand-independent hyperphosphorylation 
of the receptor and promote the activity of STAT328. 
Tie2 kinase initiates signal transduction pathways 
downstream of Dok-R and rasGAP33.  rasGAP is a GT-
Pase-activating protein and functions as a negative reg-
ulator of Ras signalling by stimulating the intrinsic rate 
of Ras GTPase activity34.  Because Ras signals have 
been implicated in VEGF expression, as well as in cell 
growth, differentiation, and tumorigenicity35–37, it is 
likely that the enhancement of VEGF expression and 
tumorigenicity by G833DTie2 may be the result of inap-
propriate signalling through Ras in ECs.  On the other 
hand, on the OSCC bearing the G2128T mutation, the 
over-expressed G697CFGFR3b protein is similarly local-
ized to the cell surface indicating that the substitution 
of glycine with cysteine might cause ligand-independent 
dimerization of FGFR molecules, which results in alter-
ations in receptor function including increased levels of 
membrane-localized FGFR3b and enhanced autophos-
phorylation activity.
 Human IMHs are benign, nonmetastatic tumors.  The 
high postoperative recurrence of IMHs has previously 
been attributed to incomplete excision.  The data pre-
sented here, however, demonstrate that there are signif-
icant characteristics of the G833D mutation with re-
spect to transforming activity and VEGF expression. 
These characteristics could reﬂ ect the clinical pheno-
type of early post-operative recurrence in the human 
G833D IMHs.  Our results and subsequent elucidation 
of Tie2-mutant-mediated signalling properties may be 
useful in terms of diagnosis of and possible therapy for 
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various forms of IMH with Tie2 as a target.  In addition, 
the apparent over-expression of G697CFGFR3b in 62% of 
the OSCC cases investigated strongly suggests that this 
particular mutation is involved in the progression of 
OSCC.  FGFR3b may therefore be an important diag-
nostic and prognostic marker for OSSC and a molecular 
target for future therapies.
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